Table 1.
Differences in exposure and treatment at index date, before and after weighting, using propensity scores
| Variable | Category | Before weighting
|
After weighting
|
||||
|---|---|---|---|---|---|---|---|
| Untreated (n = 342) | Treated (n = 424) | P | Untreated (n = 342) | Treated (n = 424) | P† | ||
| Age | < 40 | 114 (33%) | 105 (25%) | 0.030 | (30%) | (28%) | 0.958 |
| 40 < 50 | 95 (28%) | 114 (27%) | (28%) | (28%) | |||
| 50 < 60 | 73 (21%) | 118 (28%) | (23%) | (25%) | |||
| ≥ 60 | 60 (18%) | 87 (21 %) | (18%) | (19%) | |||
| Sex | Female | 172 (50%) | 139 (33%) | < 0.001 | (36%) | (36%) | 0.960 |
| Male | 170 (50%) | 285 (67%) | (64%) | (64%) | |||
| Race | Asian/other | 236 (69%) | 230 (54%) | < 0.001 | (61%) | (58%) | 0.622 |
| Black | 38 (11%) | 72 (17%) | (19%) | (18%) | |||
| White | 59 (17%) | 110 (26%) | (18%) | (22%) | |||
| Unknown | 9 (3%) | 12 (3%) | (2%) | (3%) | |||
| Index year | 2000 < 2005 | 47 (14%) | 42 (10%) | 0.187 | (17%) | (10%) | .0.845 |
| 2005 < 2010 | 220 (64%) | 295 (70%) | (63%) | (65%) | |||
| ≥ 2010 | 75 (22%) | 87 (21 %) | (20%) | (25%) | |||
| ALT | < LLN and/or Normal | 282 (82%) | 215 (51%) | < 0.001 | (64%) | (64%) | 0.221 |
| ULN ≤ 2*ULN | 42 (12%) | 108 (25%) | (15%) | (20%) | |||
| > 2*ULN | 18 (5%) | 101 (24%) | (20%) | (16%) | |||
| Weighted Charlson-Deyo score (includes liver comorbidity) | 0 | 229 (67%) | 193 (46%) | < 0.001 | (54%) | (57%) | 0.202 |
| 1 | 60 (18%) | 75 (18%) | (15%) | (15%) | |||
| 2 | 13 (4%) | 44 (10%) | (5%) | (8%) | |||
| 3 | 40 (12%) | 112 (26%) | (26%) | (20%) | |||
| Decompensated cirrhosis | No | 338 (99%) | 392 (92%) | < 0.001 | (97%) | (95%) | 0.137 |
| Yes | 4 (1%) | 32 (8%) | (3%) | (5%) | |||
| HIV co-infection | No | 333 (97%) | 380 (90%) | < 0.001 | (89%) | (92%) | 0.707 |
| Yes | 9 (3%) | 44 (10%) | (11%) | (8%) | |||
| LOG10HBVQT (viralload) | 3.6 ± 1.3 | 5.5 ± 1.9 | < 0.001 | .4.9 ± 2.5 | 4.6 ± 2.3. | 0.157 | |
| FIB4‡ | 1.8 ± 4.9 | 3.0 ± 4.1 | < 0.001 | .2.1 ± 2.3 | 2.2 ± 2.4. | 0.915 | |
| APRI‡ | 0.9 ± 5.0 | 1.56 ± 2.5 | < 0.001 | 1.7 ± 5.5. | 1.1 ± 2.4. | 0.772 | |
†
Type III analysis using Wald Chi-square test from multiple variable logistic regression.
‡
Log10 scale was used for the propensity score calculation. Original scale is presented for ease of interpretation.
ALT, alanine aminotransferase; APRI, AST to platelet ratio index; FIB4, Fibrosis-4; HBV, hepatitis B virus; HIV, human immunodeficiency virus; MPC, monthly percentage change; ULN, upper limit of normal.